{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:40:50Z","timestamp":1785163250452,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.pnpbp.2011.11.004","type":"journal-article","created":{"date-parts":[[2011,11,17]],"date-time":"2011-11-17T10:20:31Z","timestamp":1321525231000},"page":"313-317","source":"Crossref","is-referenced-by-count":11,"title":["Effect of olanzapine orally disintegrating tablet versus oral standard tablet on body weight in patients with schizophrenia: a randomized open-label trial"],"prefix":"10.1016","volume":"36","author":[{"given":"Ichiro","family":"Kusumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhumi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Kohsaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Tochigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsukasa","family":"Koyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.11.004_bb0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hup.819","article-title":"Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients","volume":"22","author":"Arranz","year":"2007","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0015","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3109\/15622975.2010.505663","article-title":"Patients\u2019 preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study","volume":"11","author":"Bitter","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.schres.2006.09.025","article-title":"Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study","volume":"90","author":"Bobes","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0115","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/hup.921","article-title":"Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial","volume":"23","author":"Chawla","year":"2008","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.eurpsy.2007.06.004","article-title":"Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets","volume":"22","author":"Crocq","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0035","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00213-004-1951-2","article-title":"Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets","volume":"175","author":"De Haan","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","article-title":"Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course","volume":"43","author":"Gebhardt","year":"2009","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0050","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.schres.2007.12.476","article-title":"Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects","volume":"101","author":"Graham","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0055","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1017\/S0033291700050182","article-title":"A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity","volume":"13","author":"Hogan","year":"1983","journal-title":"Psychol Med"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/hup.933","article-title":"Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain","volume":"23","author":"Karagianis","year":"2008","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.schres.2009.05.024","article-title":"A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study","volume":"113","author":"Karagianis","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0070","series-title":"Positive and Negative Syndrome Scale (PANSS) Rating Manual","author":"Kay","year":"1991"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0075","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.jcp.0000161501.65890.22","article-title":"Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders","volume":"25","author":"Kinon","year":"2005","journal-title":"J Clin Psychopharmacology"},{"issue":"Suppl","key":"10.1016\/j.pnpbp.2011.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1177\/0091270005283839","article-title":"Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers","volume":"46","author":"Markowitz","year":"2006","journal-title":"J Clin Pharmacology"},{"issue":"Suppl.18","key":"10.1016\/j.pnpbp.2011.11.004_bb0120","first-page":"36","article-title":"Abnormalities of glucose metabolism associated with atypical antipsychotic drugs","volume":"65","author":"Newcomer","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/jcp.0b013e3181602fe6","article-title":"Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol","volume":"28","author":"Saddichha","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0100","series-title":"WHO QOL 26","author":"Tasaki","year":"1997"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0105","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4088\/JCP.08m04654yel","article-title":"Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study","volume":"71","author":"Vidarsdottir","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1530\/EJE-09-0433","article-title":"Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets","volume":"162","author":"Vidarsdottir","year":"2010","journal-title":"Eur J Endocrinology"},{"key":"10.1016\/j.pnpbp.2011.11.004_bb0125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF: quality of life assessment","volume":"28","year":"1998","journal-title":"Psychol Med"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611003198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611003198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,28]],"date-time":"2018-11-28T06:56:59Z","timestamp":1543388219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584611003198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S0278584611003198"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.11.004","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}